Literature DB >> 12208592

Effects of metoprolol in chagasic patients with severe congestive heart failure.

Diego F Dávila1, Francisco Angel, Gabriela Arata de Bellabarba, Jose H Donis.   

Abstract

BACKGROUND: Beta-blockers are the most effective and promising treatment for congestive heart failure secondary to left ventricular dysfunction and sympathetic activation.
METHODS: Since chagasic patients with severe congestive heart failure have left ventricular systolic dysfunction and neurohormonal activation, we administered metoprolol to nine chagasic patients who were in severe congestive heart failure. Metoprolol (5 mg p.o. daily) was uptitrated on a weekly basis.
RESULTS: Patients were receiving digitalis, diuretics and angiotensin converting enzyme inhibitors and had left ventricular dilatation (6.77+/-0.89 cm), depressed ejection fraction (0.20+/-0.06), low systolic blood pressure (93+/-11 mm Hg), sinus tachycardia (115+/-17 beats/min) and sympathetic activation 400+/-246 pg/ml). One patient was in New York Heart Association Functional class III and eight patients were in functional class IV. At the end of the fifth week of treatment (metoprolol 25 mg), seven patients were in functional class III and two were in functional class II. Heart rate decreased to 85+/-15 beats/min (P<0.05) and the systolic blood pressure increased to 108+/-18 mm Hg (P<0.01). There were no significant changes in left ventricular ejection fraction. By the end of the tenth week of treatment (metoprolol 50 mg), four patients were now in functional class I and five were in functional class II. Left ventricular ejection fraction increased to 0.27+/-0.05 (P<0.01) and the left ventricular systolic diameter decreased from 6.38+/-0.90 at baseline to 5.89+/-0.59 and 5.76+/-0.96 after 25 and 50 mg of metoprolol treatment, respectively (P<0.04). Plasma norepinephrine decreased non-significantly to 288+/-91 pg/ml.
CONCLUSION: Beta-blockers improve the clinical status and the left ventricular function of chagasic patients with severe congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208592     DOI: 10.1016/s0167-5273(02)00181-x

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

1.  Chagas Heart Failure in Patients from Latin America.

Authors:  Reinaldo B Bestetti
Journal:  Card Fail Rev       Date:  2016-11

2.  Emerging and under-recognized Chagas cardiomyopathy in non-endemic countries.

Authors:  Joana Cortez; Rui Providência; Evelise Ramos; Cristina Valente; Jorge Seixas; Manuela Meruje; António Leitão-Marques; António Vieira
Journal:  World J Cardiol       Date:  2012-07-26

Review 3.  Epidemiology of Chagas disease in Europe: many calculations, little knowledge.

Authors:  Jörn Strasen; Tatjana Williams; Georg Ertl; Thomas Zoller; August Stich; Oliver Ritter
Journal:  Clin Res Cardiol       Date:  2013-08-29       Impact factor: 5.460

4.  The effect of beta-blockade on myocardial remodelling in Chagas' cardiomyopathy.

Authors:  Walace de Souza Pimentel; Felix José Alvarez Ramires; Barbara Maria Lanni; Vera Maria Cury Salemi; Angelina Morand Bianchi Bilate; Edecio Cunha-Neto; Adriana Morgan de Oliveira; Fábio Fernandes; Charles Mady
Journal:  Clinics (Sao Paulo)       Date:  2012-09       Impact factor: 2.365

Review 5.  Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy.

Authors:  Claudio A Muratore; Adrian Baranchuk
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

Review 6.  Treatment of Chagas cardiomyopathy.

Authors:  Fernando A Botoni; Antonio Luiz P Ribeiro; Carolina Coimbra Marinho; Marcia Maria Oliveira Lima; Maria do Carmo Pereira Nunes; Manoel Otávio C Rocha
Journal:  Biomed Res Int       Date:  2013-11-24       Impact factor: 3.411

7.  Carvedilol enhances the antioxidant effect of vitamins E and C in chronic Chagas heart disease.

Authors:  Patrícia Budni; Roberto Coury Pedrosa; Eduardo Monguilhott Dalmarco; Juliana Bastos Dalmarco; Tânia Sílvia Frode; Danilo Wilhelm Filho
Journal:  Arq Bras Cardiol       Date:  2013-09-06       Impact factor: 2.000

8.  TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas' heart disease.

Authors:  Roberto Rodrigues Ferreira; Rayane da Silva Abreu; Glaucia Vilar-Pereira; Wim Degrave; Marcelo Meuser-Batista; Nilma Valéria Caldeira Ferreira; Otacílio da Cruz Moreira; Natália Lins da Silva Gomes; Elen Mello de Souza; Isalira P Ramos; Sabine Bailly; Jean-Jacques Feige; Joseli Lannes-Vieira; Tania C de Araújo-Jorge; Mariana Caldas Waghabi
Journal:  PLoS Negl Trop Dis       Date:  2019-07-31

9.  Autonomic dysfunction and beta blocker therapy in Chagas heart disease.

Authors:  Reinaldo B Bestetti; Augusto Cardinalli-Neto
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

10.  Cardiac autonomic control mechanisms in the pathogenesis of chagas' heart disease.

Authors:  Diego F Dávila; Jose H Donis; Gabriela Arata de Bellabarba; Vanesa Villarroel; Francisco Sanchez; Lisbeth Berrueta; Siham Salmen; Barbara Das Neves
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.